GlassScriptPhysician profile
Jonathan Lee Steinberg
NPI 1770087686
$4,722.27
in general payments reported to CMS, 2019-2025
21 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $1,136 · 2024: $1,561 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,457 · Education: $29.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,456.75 |
| Education | $29.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,545.16 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Balt USA, LLC | $903.83 | 2024-2025 | Prestige Coil System |
| Janssen Biotech, INC. | $555.87 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $249.51 | 2025 | General - Hemostasis, Overstitch Endoscopic Suturing System |
| Mallinckrodt Hospital Products INC. | $183.33 | 2023-2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $169.81 | 2024 | Voquezna |
| Steris Corporation | $145.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.57 | 2022-2025 | Gattex, Entyvio, Eohilia |
| Ardelyx, INC. | $129.83 | 2025 | Ibsrela |
| Novo Nordisk INC | $124.53 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $120.30 | 2023 | Dupixent |
| Genzyme Corporation | $99.21 | 2024-2025 | |
| Lilly USA, LLC | $94.21 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $51.82 | 2024-2025 | Livdelzi |
| Alnylam Pharmaceuticals INC. | $42.64 | 2024 | Givlaari |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $40.13 | 2023-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $33.00 | 2025 | Rezdiffra |
| Celltrion USA INC. | $29.12 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $23.56 | 2023 | Rebyota |
| Sumitomo Pharma America, INC. | $23.14 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $14.40 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.